New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process—A Workshop
March 21, 2012
20 F Street NW Conference Center
20 F Street, NW
Washington, DC 20001
WORKSHOP OBJECTIVES
• To examine the impact of and investment in the use of genetic and genomic data in drug development.
• To discuss how genomic and genetic data have been and will be used in the drug development process to improve aspects such as target identification, clinical trial design, pharmacogenomic approaches, biomarker development, and understanding of disease biology.
• To investigate the economic drivers, incentives, and models for genomic-based strategies for drug development.
8:30–8:35 A.M. |
WELCOMING REMARKS Wylie Burke, Roundtable Chair |
8:35–8:45 A.M. |
CHARGE TO WORKSHOP SPEAKERS AND PARTICIPANTS Geoffrey Ginsburg |
8:45–10:15 A.M. |
CURRENT LANDSCAPE Session Moderator: Aidan Power, Pfizer Inc. |
8:45–9:00 A.M. |
Current Use of Genetic and Genomic Strategies in Drug Development Nicholas Davies |
9:00–9:15 A.M. |
Economic Incentives for Genetic and Genomic Strategies Mark Trusheim |
9:15–9:30 A.M. |
Perceived Challenges in Genomic-Based Drug Development Garret A. FitzGerald |
9:30–10:15 A.M. |
Discussion with Speakers and Attendees |
10:15–10:30 A.M. |
BREAK |
10:30 A.M.–12:15 P.M. |
DRUG DISCOVERY AND DEVELOPMENT: CASE STUDIES OF GENOMICS-BASED DRUG DEVELOPMENT Session Moderator: Michelle Penny, Eli Lilly and Company |
10:30–10:50 A.M. |
Development of Crizotinib for Treatment of Non-Small-Cell Lung Cancer Steffan N. Ho |
10:50–11:10 A.M. |
Use of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia Laura Nisenbaum |
11:10–11:30 A.M. |
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller |
11:30 A.M.–12:15 P.M. |
Discussion with Speakers and Attendees |
12:15–1:00 P.M. |
WORKING LUNCH |
1:00–2:15 P.M. |
UTILITY OF EMERGING GENOMICS TECHNOLOGY IN DRUG DEVELOPMENT Session Moderator: Geoffrey Ginsburg, Duke University |
1:00–1:15 P.M. |
Large-Scale Whole-Genome Sequencing for Disease Understanding, Drug Development, and Genomic Medicine Radoje Drmanac |
1:15–1:30 P.M. |
Clinical Next Generation Sequencing—Value to Drug Developers Gary Palmer |
1:30–1:45 P.M. |
Pharma Perspective Jane Fridlyand |
1:45–2:15 P.M. |
Discussion with Speakers and Attendees |
2:15–4:15 P.M. |
EVOLVING PARADIGMS Session Moderator: Sharon Terry, Genetic Alliance |
2:15–2:30 P.M. |
Foundations and Drug Development Walter Capone |
2:30–2:45 P.M. |
Genomics and Regulatory Science Michael Pacanowski |
2:45–3:00 P.M. |
BREAK |
3:00–3:15 P.M. |
Repurposing of Drugs Christopher Austin |
3:15–3:30 P.M. |
Pharmacy Benefit Management and Pharmacogenomics Felix W. Frueh |
3:30–4:15 P.M. |
Discussion with Speakers and Attendees |
4:15–5:30 P.M. |
LEADING THE STRATEGY FOR PERSONALIZED MEDICINE: PHARMA, GOVERNMENT, ACADEMIA—HOW DO WE ALL WORK TOGETHER? Session Moderator: Thomas Lehner, Discussants: Deborah Dunsire |
Victor Dzau Margaret Hamburg Kathy Hudson |
|
5:30–5:45 P.M. |
CONCLUDING REMARKS Geoffrey Ginsburg |
5:45 P.M. |
ADJOURN |